Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.65 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.65 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.65 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.65 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.65 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.44 |
| ▸ | ABL1 | P00519 | 3/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.40 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | PRKACG | P22612 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138001 | 1.00 | PIK3CA (0.65) | PIK3CAPIK3CDPIK3CGPIK3CBPI4KB | |
| SCHEMBL3131409 | 0.93 | PIK3CA (0.65) | PIK3CAPIK3CDPIK3CGPIK3CBPI4KB | |
| SCHEMBL3131395 | 0.93 | PIK3CA (0.65) | PIK3CAPIK3CDPIK3CGPIK3CBPI4KB | |
| SCHEMBL3141598 | 0.91 | PIK3CA (0.65) | PIK3CAPIK3CDPIK3CGPIK3CBPI4KB | |
| SCHEMBL3141610 | 0.91 | PIK3CA (0.65) | PIK3CAPIK3CDPIK3CGPIK3CBPI4KB | |
| SCHEMBL13415486 | 0.89 | PIK3CA (0.66) | PIK3CAPIK3CDPIK3CGPIK3CBPI4KB | |
| SCHEMBL3146317 | 0.89 | PIK3CA (0.68) | PIK3CAPIK3CDPIK3CGPIK3CBPI4KB | |
| SCHEMBL3146303 | 0.89 | PIK3CA (0.68) | PIK3CAPIK3CDPIK3CGPIK3CBPI4KB | |
| SCHEMBL3146910 | 0.89 | PIK3CA (0.65) | PIK3CAPIK3CDPIK3CGPIK3CBPI4KB | |
| SCHEMBL3146896 | 0.89 | PIK3CA (0.65) | PIK3CAPIK3CDPIK3CGPIK3CBPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CD 2/4885PIK3CG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.